Navigation Links
Drug that restricts blood supply to prostate tumors delays disease progression
Date:6/8/2010

A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.

Tasquinimod is a so-called "anti-angiogenesis" drug that squeezes off blood supply to prostate tumors by blocking new blood vessel development. Tumors require these vast networks of blood vessels to supply nutrients.

The multicenter trial at seven institutions, including Johns Hopkins, enrolled prostate cancer patients whose disease had spread to take a once-daily pill for four weeks. At six months, 57 percent of men taking tasquinimod had no disease progression as compared with 33 percent taking a placebo. Overall, the drug added approximately 12 weeks of time that the disease did not worsen (progression-free survival).

The most common side effects included gastrointestinal problems, fatigue and bone pain, and some rare occurrences of heart attack, stroke and deep vein thrombosis.

"Given these results, we feel it is reasonable to move forward with Phase III studies," says Michael Carducci, M.D., professor at the Johns Hopkins Kimmel Cancer Center, who will lead the next phase of an international study of the drug. "After exploring the drug as a single agent, we may study it in combination approaches with other prostate cancer drugs."

Research leading to tasquinimod began in the early 1990s when John Isaacs, Ph.D., professor at the Johns Hopkins Kimmel Cancer Center, found that a drug called linomide, which had been tested in multiple sclerosis, restricted blood supply to prostate tumors. However, the drug's cardiac side effects were too toxic for humans, so Isaacs in collaboration with the pharmaceutical company Active Biotech identified tasquinimod for clinical testing after searching for drugs similar to linomide with the same blood vessel action but with less toxicity.

Isaacs says that tasquinimod works by stopping new blood vessel development around the tumor, but does not make existing vasculature disappear. "The idea for anti-angiogenesis drugs is not to prevent tumors from developing; rather, it is to stabilize disease," says Isaacs, who is conducting additional laboratory studies to identify the drug's precise cellular target.

Funding for the study was provided by Active Biotech, manufacturer of tasquinimod, and the U.S. Department of Defense.

Carducci is a paid consultant to Active Biotech and the terms of this arrangement are being managed in accordance with policies set by the Johns Hopkins University.


'/>"/>

Contact: Vanessa Wasta
wastava@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Psychologists Say New Jerseys Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money
2. ASCO data show serum DNA blood tests detect cancers with high sensitivity and specificity
3. Glucose Tattoo Could Track Blood Sugar Levels for Diabetics
4. DUI Phoenix Attorney Earns Not Guilty Verdict and Hung Jury in .104 Blood Alcohol Content DUI Case
5. First paper dipstick test for determining blood type
6. Nottingham research leads to blood test for early detection of cancer
7. Blood flows differently through the brains of schizophrenic patients
8. Report Finds Control of High Blood Pressure Improving
9. Frequent Doctor Visits Help Diabetics Control Blood Pressure
10. Fewer Sugary Drinks, Less High Blood Pressure
11. A new cancer vaccine starves tumors of blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... Houston ... Center, is currently offering complimentary consultations and financing for orthodontics for a limited ... bite irregularities and learn about their orthodontic options. Walk-in, late-evening, Saturday, and same-day ...
(Date:1/16/2017)... MO (PRWEB) , ... January 16, 2017 , ... St. Louisans are well-aware of the ... , This year’s influenza shot seems to be having no effect on keeping ... at least half of the people around are coughing, sneezing, or sniffling ...
(Date:1/16/2017)... ... , ... San Francisco dentist, Dr. Ben Amini , the founder at ... is capable of taking digital impressions of teeth and gums. Conventional bite impressions have ... restorations , in terms of speed, efficiency and patient comfort. Increasingly, digital impressions are ...
(Date:1/15/2017)... ... 15, 2017 , ... Whole Health Supply, LLC is announcing the release of an updated version ... for purchase. , The 2017 edition has wide jaws that will accommodate nails up ... as well as diabetics. This handle is reinforced for extra strength when pressing down on ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor Rock Climbing Gym is ... wraps up on the 14,000+ square foot climbing gym, the owners anticipate to open ... in New Jersey and two in New York. With this being its first location ...
Breaking Medicine News(10 mins):
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP ... of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ... through October 31, 2016 (the "Class Period"). Zimmer ... and markets orthopaedic reconstructive products, such as knee and hip ... ...
(Date:1/13/2017)... Eli Lilly and Company (NYSE: ... ) announced today that the U.S. Food and Drug ... new drug application (NDA) for investigational baricitinib, a once-daily ... rheumatoid arthritis (RA). The NDA for baricitinib was submitted ... FDA extended the action date to allow time to ...
(Date:1/13/2017)... New York , January 13, 2017 ... rising prevalence of AIDS will collectively contribute to the demand ... expected to reach a value of US$ 551.0 Mn by ... will remain the most lucrative markets for western blotting, ... lead the market globally. ...
Breaking Medicine Technology: